CEO of Serum Institute of India (SII), Adar Poonawalla addressed a virtual conference with Executive Chairperson of Biocon Biologics (BBL) Kiran Mazumdar Shaw to announce their strategic alliance on September 17. Reportedly, SII was looking to scale up its research facilities with BBL. Also, the alliance aims to increase the production of Covishield Vaccines from 160 million doses monthly to 200 million doses from October.
Courtesy: The Indian Express
Bengaluru-based biopharmaceutical company Biocon on October 7 announced an injection of capital worth Rs 1,125 crore ($150 million) by investment giant Goldman Sachs in its subsidiary Biocon Biologics. Goldman will be issued an Optionally Convertible Debentures in return of the investment. The capitalization will help Biocon Biologics invest in its R&D and manufacturing and further expansion in the global market. Interestingly, this is… read-more
Courtesy: The Times of India